In vitro properties of antimicrobial bromotyrosine alkaloids

Journal of Medical Microbiology

Volumn 55, Issue 4, 2006, Pages 407-415

  Pick, Neora ^a   Rawat, Mamta ^a,b   Arad, Dorit ^a   Lan, Jiong ^c   Fan, Junfa ^c   Kende, Andrew S ^c   Av Gay, Yossef ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CALIFORNIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; AMIDASE; ANTIBIOTIC AGENT; BACTERIAL ENZYME; BIS(TRIFLUOROACETIC ACID) N [[(4 AMINOIMINOMETHYL)AMINO]BUTYL] 3 [4 [[4 (AMINOIMINOMETHYL)AMINO]BUTOXY] 3,5 DIBROMOPHENYL] 2 HYDROXYIMINOPROPIONAMIDE; BIS(TRIFLUOROACETIC ACID) N [[(6 AMINOIMINOMETHYL)AMINO]HEXYL] 3 [4 (3 AMINOPROPOXY) 3,5 DIBROMOPHENYL] 2 BENZYLOXYIMINOPROPIONAMIDE; BIS(TRIFLUOROACETIC ACID) N [[(6 AMINOIMINOMETHYL)AMINO]HEXYL] 3 [4 (3 AMINOPROPOXY) 3,5 DIBROMOPHENYL] 2 HYDROXYIMINOPROPIONAMIDE; BIS(TRIFLUOROACETIC ACID) N [[(6 AMINOIMINOMETHYL)AMINO]HEXYL] 3 [4 (3 AMINOPROPOXY) 3,5 DICHLOROPHENYL] 2 HYDROXYIMINOPROPIONAMIDE; BIS(TRIFLUOROACETIC ACID) N [[(6 AMINOIMINOMETHYL)AMINO]HEXYL] 3 [4 [[4 (AMINOIMINOMETHYL)AMINO]BUTOXY] 3,5 DIBROMOPHENYL] 2 HYDROXYIMINOPROPIONAMIDE; BROMOTYROSINE ALKALOID; EXEG 1706; EXEG 1707; EXEG 1710; EXEG 1712; EXEG 3022; METICILLIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; DRUG STRUCTURE; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; MAMMAL CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL;

ALKALOIDS; ANTI-BACTERIAL AGENTS; BACTERIA; CELL LINE; HUMANS; MACROPHAGES; MODELS, CHEMICAL; MOLECULAR STRUCTURE; MONOCYTES; TYROSINE;

EID: 33645464951     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.46319-0     Document Type: Article

References (34)

1. Arad, D. & Av-Gay, Y. (2003). Antimicrobial compounds against Staphylococci, Mycobacteria and other infectious agents. US patent application WO 2004012506 and WO 2003087127.
2. Bartley, J. (2002). First case of VRSA identified in Michigan. Infect Control Hosp Epidemiol 23, 480.
3. Basta, S., Knoetig, S. M., Spagnuolo-Weaver, M., Allan, G. & McCullough, K. C. (1999). Modulation of monocytic cell activity and virus susceptibility during differentiation into macrophages. J Immunol 162, 3961-3969.
4. Casewell, M. W. & Hill, R. L. (1986). The carrier state: methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 18 (Suppl. A), 1-12.
5. Cassone, M., Campanile, F., Pantosti, A., Venditti, M. & Stefani, S. (2004). Identification of a variant "Rome clone" of methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin, responsible for an outbreak in an intensive care unit. Microb Drug Resist 10, 43-49.
6. Coccia, E. M., Del Russo, N., Stellacci, E., Testa, U., Marziali, G. & Battistini, A. (1999). STAT1 activation during monocyte to macrophage maturation: role of adhesion molecules. Int Immunol 11, 1075-1083.
7. Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. (1999). Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282, 677-686.
8. Gessani, S., Testa, U., Varano, B. & 7 other authors (1993). Enhanced production of LPS-induced cytokines during differentiation of human monocytes to macrophages. Role of LPS receptors. J Immunol 151, 3758-3766.
9. Kende, A. S., Lan, J. & Fan, J. (2004). Total synthesis of a dibromotyrosine alkaloid inhibitor of mycothiol S-conjugate amidase. Tetrahedron Lett 45, 133-135.
10. Kluytmans, J. A., Mouton, J. W., Ijzerman, E. P., Vandenbroucke-Grauls, C. M., Maat, A. W., Wagenvoort, J. H. & Verbrugh, H. A. (1995). Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 171, 216-219.
11. Lowy, F. D. (1998). Staphylococcus aureus infections. N Engl J Med 339, 520-532.
12. Mallaval, F. O., Carricajo, A., Delavenna, F. & 7 other authors (2004). Detection of an outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a French hospital. Clin Microbiol Infect 10, 459-461.
13. Maynes, J. T., Garen, C., Cherney, M. M., Newton, G., Arad, D., Av-Gay, Y., Fahey, R. C. & James, M. N. (2003). The crystal structure of 1-D-myo-inosityl 2-acetamido-2-deoxy-α-D-glucopyranoside deacetylase (MshB) from Mycobacterium tuberculosis reveals a zinc hydrolase with a lactate dehydrogenase fold. J Biol Chem 278, 47166-47170.
14. McCarthy, A. A., Knijff, R., Peterson, N. A. & Baker, E. N. (2003). Crystallization and preliminary X-ray analysis of N-acetyl-1-D-myoinosityl-2- deoxy-α-D-glucopyranoside deacetylase (MshB) from Mycobacterium tuberculosis. Acta Crystallogr D Biol Crystallogr 59, 2316-2318.
15. National Committee for Clinical Laboratory Standards (1993). Performance standards for antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard M7-T2, 2nd edn. Villanova, PA: National Committee for Clinical Laboratory Standards.
16. Negi, S. S., Gupta, S. & Lal, S. (2003). Drug resistance in tuberculosis in Delhi: a 2 year profile (2001-2002). J Commun Dis 35, 74-81.
17. Newton, G. L., Arnold, K., Price, M. S. & 7 other authors (1996). Distribution of thiols in microorganisms: mycothiol is a major thiol in most actinomycetes. J Bacteriol 178, 1990-1995.
18. Newton, G. L., Av-Gay, Y. & Fahey, R. C. (2000). A novel mycothiol-dependent detoxification pathway in mycobacteria involving mycothiol S-conjugate amidase. Biochemistry 39, 10739-10746.
19. Nicholas, G. M., Newton, G. L., Fahey, R. C. & Bewley, C. A. (2001). Novel bromotyrosine alkaloids: inhibitors of mycothiol S-conjugate amidase. Org Lett 3, 1543-1545.
20. Nicholas, G. M., Eckman, L. L., Ray, S., Hughes, R. O., Pfefferkorn, J. A., Barluenga, S., Nicolaou, K. C. & Bewley, C. A. (2002). Bromotyrosine-derived natural and synthetic products as inhibitors of mycothiol-S-conjugate amidase. Bioorg Med Chem Lett 12, 2487-2490.
21. Pick, N., Cameron, S., Arad, D. & Av-Gay, Y. (2004). Screening of compounds toxicity against human monocytic cell line-THP-1 by flow cytometry. Biol Proced Online 6, 220-225.
22. Rawat, M., Newton, G., Ko, M., Martinez, G., Fahey, R. C. & Av-Gay, Y. (2002). Mycothiol-deficient Mycobacterium smegmatis mutants are hypersensitive to alkylating agents, free radicals, and antibiotics. Antimicrob Agents Chemother 46, 3348-3355.
23. Rawat, M., Kovacevic, S., Billman-Jacobe, H. & Av-Gay, Y. (2003). Inactivation of mshB, a key gene in the mycothiol biosynthesis pathway in Mycobacterium smegmatis. Microbiology 149, 1341-1349.
24. Rawat, M., Uppal, M., Newton, G., Steffek, M., Fahey, R. C. & Av-Gay, Y. (2004). Targeted mutagenesis of the Mycobacterium smegmatis mca gene, encoding a mycothiol-dependent detoxification protein. J Bacteriol 186, 6050-6058.
25. Sanford, M. D., Widmer, A. F., Bale, M. J., Jones, R. N. & Wenzel, R. P. (1994). Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 19, 1123-1128.
26. Schwalbe, R. S., Stapleton, J. T. & Gilligan, P. H. (1987). Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 316, 927-931.
27. Tuazon, C. U. & Sheagren, J. N. (1974). Increased rate of carriage of Staphylococcus aureus among narcotic addicts. J Infect Dis 129, 725-727.
28. Tuazon, C. U., Perez, A., Kishaba, T. & Sheagren, J. N. (1975). Staphylococcus aureus among insulin-injecting diabetic patients. An increased carrier rate. JAMA 231, 272.
29. Wagner, J., Kallen, J., Ehrhardt, C, Evenou, J. P. & Wagner, D. (1998). Rational design, synthesis, and X-ray structure of selective noncovalent thrombin inhibitors. J Med Chem 41, 3664-3674.
30. Weinke, T., Schiller, R., Fehrenbach, F. J. & Pohle, H. D. (1992). Association between Staphylococcus aureus nasopharyngeal colonization and septicemia in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 11, 985-989.
31. Wenzel, R. P. & Perl, T. M. (1995). The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 31, 13-24.
32. World Health Organization (2002). Tuberculosis, WHO fact sheet no. 104. Geneva: World Health Organization.
33. Yanisch-Perron, C., Vieira, J. & Messing, J. (1985). Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33, 103-119.
34. Yu, V. L., Goetz, A., Wagener, M., Smith, P. B., Rihs, J. D., Hanchett, J. & Zuravleff, J. J. (1986). Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 315, 91-96.